EMA will define its own trial data shortcuts, not just follow FDA
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is pressing on with plans to develop a formal framework on how companies may gauge the effects of an investigational drug on a target population by extrapolating available data from related studies involving other populations, thereby avoiding the need to conduct unnecessary clinical studies. But discussions at a recent meeting suggest it will not simply adopt wholesale the approach that the US FDA has espoused.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.